PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth above 1.5x AXSM's 3.07%. Michael Burry would check for spending discipline.
12.93%
G&A growth while AXSM reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
14.34%
Operating expenses growth above 1.5x AXSM's 7.28%. Michael Burry would check for inefficiency.
14.34%
Total costs growth above 1.5x AXSM's 7.28%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A growth 1.25-1.5x AXSM's 3.71%. Martin Whitman would scrutinize asset base.
-16.61%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-20.40%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-20.61%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.76%
Share count reduction exceeding 1.5x AXSM's 2.00%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.